Latest Clinical & Research News
Specialty: Urology
Adam S. Kibel, MD, and Anna Plym, PhD, of the Division of Urology, and colleagues conducted the most comprehensive study to date on the role of inherited DNA damage response (DDR) genes in aggressive prostate cancer. They report high carrier frequency of DDR gene alterations in lethal cases irrespective of ancestry.
Read More...
Adam S. Kibel, MD, and Jiun-Hung Geng, of the Brigham’s Division of Urology, and colleagues recently conducted the first study of how the combination of metabolic syndrome and its treatment affect response to androgen deprivation therapy in castration-sensitive prostate cancer.
Read More...
Using the world’s largest pharmacovigilance database, Eugene B. Cone, MD, Quoc-Dien Trinh, MD, and colleagues determined the risk of cardiac adverse events is increased substantially with abiraterone and not at all with enzalutamide.
Read More...
Building a racially/ethnically representative urology workforce is becoming even more important. Elodi J. Dielubanza, MD, associate surgeon in the Division of Urology at Brigham and Women’s Hospital, and colleagues recently conducted the first study that describes demographic trends in urologic subspecialties.
Read More...
George E. Haleblian, MD, urologic surgeon in the Division of Urology at the Brigham, and colleagues applied TDABC to acute urolithiasis. They report wide variation in costs between care pathways, suggesting opportunities to trim inefficient or wasteful services.
Read More...
Elodi Dielubanza, MD, associate surgeon in the Brigham’s Division of Urology, is seeking to normalize female urinary tract and pelvic floor disorders. She helps patients with these disorders to restore their normal daily function through surgery, medications, physical therapy and behavior modification.
Read More...
While traditional tumor boards are common at most academic medical centers, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has taken its 10-year-old tumor board to the next level by integrating molecular pathology into their discussions.
The Division of Urology at Brigham and Women’s Hospital provides expert, individualized care for a range of urological conditions. Because many urological treatments have similar clinical outcomes, division surgeons are gathering data called patient-reported outcome measures (PROMs). They plan to use PROMs to better identify the nuances of treatment outcomes and determine how these outcomes affect quality of life for individual patients.
Based on clinical expertise and patient volume, the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) is one of the top programs in the country for the treatment of genitourinary cancers. The integrated center draws on the expertise of a multidisciplinary team of specialists to provide exceptional patient care.
In response to the COVID-19 pandemic, the Brigham’s Division of Urology has harnessed telehealth technology to ensure continuation of care for patients and improve patient outcomes.